Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2023 | Developing antibodies against pathogenic TDP-43 in ALS

Johanne Kaplan, PhD, ProMIS™ Neurosciences, Inc., Cambridge, MA, introduces the TDP-43 program for amyotrophic lateral sclerosis (ALS) at ProMIS™ Neurosciences, Inc. Evidence suggests that the relocalization and accumulation of misfolded TDP-43 is key in ALS pathogenesis. The team has been looking to develop antibodies that are selective for pathogenic TDP-43 by identifying conformational epitopes only present on the misfolded form of the protein. The lead candidate, PMN267, shows selectivity for misfolded TDP-43 and initial pre-clinical data suggests it can block prion-like propagation and improve motor function in mice. There are currently two configurations of PMN267 in development: an intracellular intrabody to aid clearance of pathogenic aggregates inside cells and an extracellular antibody aimed at blocking propagation. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Kaplan is an employee of ProMIS Neurosciences.